Departamento de Enfermería, Fisioterapia y Medicina, Universidad de Almería, Almería, Spain.
Facultad de Psicología, Universidad de Almería, Almería, Spain.
J Sex Med. 2019 Oct;16(10):1518-1528. doi: 10.1016/j.jsxm.2019.07.026. Epub 2019 Sep 6.
Although fibromyalgia symptoms negatively affect patients' sexual life, sexual desire in women diagnosed with fibromyalgia has been understudied.
To describe and compare sexual desire in women diagnosed with fibromyalgia and healthy control women, and to investigate the influence of fibromyalgia and its pharmacologic treatment on sexual desire among women diagnosed with fibromyalgia.
164 women diagnosed with fibromyalgia participated in the study. Participants' sexual desire, fibromyalgia symptoms, symptom interference in daily life activities, and perceived quality of life were measured. Further sociodemographic and health-related data were also recorded. 87 healthy women were selected as a control group, and their sexual desire was compared with those of women diagnosed with fibromyalgia.
Main outcome measures included the Sexual Desire Inventory and the Fibromyalgia Impact Questionnaire.
When compared with healthy control subjects, women diagnosed with fibromyalgia exhibited a significantly lower mean score on total desire (47.92 ± 17.48 vs 26.33 ± 21.95; P < .001), solitary desire (10.52 ± 5.96 vs 5.74 ± 7.01; P < .001), and dyadic desire (37.40 ± 13.98 vs 20.59 ± 16.94; P < .001). Women diagnosed with fibromyalgia who were taking antidepressants scored significantly lower on dyadic desire (P < .001), solitary desire (P < .001), and total desire (P < .001) than those who were not. Furthermore, a negative correlation between desire (dyadic and solitary) and Revised Fibromyalgia Impact Questionnaire (total and all subscales) was found. Linear regression showed that taking antidepressants, age, and the total Fibromyalgia Impact Questionnaire score explained 16% of the variance of total desire.
Knowing how fibromyalgia symptoms and their pharmacologic treatment affect women's sexual desire may have implications for designing care strategies according to individual needs.
STRENGTHS & LIMITATIONS: To the best of our knowledge, this is the first study that focuses on studying the impact of fibromyalgia on dyadic and solitary sexual desire. Limitations are related to having used an online questionnaire for data collection, having recruited the participants through a convenience sampling technique and not being able to isolate whether certain results are related to fibromyalgia symptoms or are side effects of the pharmacologic treatment used for symptom control.
Fibromyalgia impact seems to negatively influence dyadic and solitary sexual desire in women. In addition, other factors such as age or taking antidepressant drugs may result in lower sexual desire in these patients. López-Rodríguez MM, Pérez Fernández A, Hernández-Padilla JM, et al. Dyadic and Solitary Sexual Desire in Patients With Fibromyalgia: A Controlled Study. J Sex Med 2019;16:1518-1528.
尽管纤维肌痛症状会对患者的性生活产生负面影响，但患有纤维肌痛症女性的性欲问题仍研究不足。
描述和比较纤维肌痛症女性与健康对照组女性的性欲，并探讨纤维肌痛症及其药物治疗对纤维肌痛症女性性欲的影响。
164 名纤维肌痛症女性参与了这项研究。测量了参与者的性欲、纤维肌痛症症状、症状对日常生活活动的干扰以及感知的生活质量。还记录了其他社会人口学和健康相关数据。选择 87 名健康女性作为对照组，并将其性欲与纤维肌痛症女性的性欲进行比较。
主要观察指标包括性欲量表和纤维肌痛症影响问卷。
与健康对照组相比，纤维肌痛症女性的总欲望评分（47.92±17.48 对 26.33±21.95；P<0.001）、单一欲望评分（10.52±5.96 对 5.74±7.01；P<0.001）和双人性欲评分（37.40±13.98 对 20.59±16.94；P<0.001）明显较低。正在服用抗抑郁药的纤维肌痛症女性在双人性欲（P<0.001）、单一欲望（P<0.001）和总欲望（P<0.001）方面的评分明显较低。此外，欲望（双人性欲和单一性欲）与修订后的纤维肌痛症影响问卷（总分和所有分量表）之间存在负相关。线性回归显示，服用抗抑郁药、年龄和纤维肌痛症影响问卷总分解释了总欲望变化的 16%。
了解纤维肌痛症症状及其药物治疗如何影响女性的性欲，可能有助于根据个体需求制定护理策略。
据我们所知，这是第一项专门研究纤维肌痛症对双人性欲和单一性欲影响的研究。局限性与使用在线问卷进行数据收集、通过方便抽样技术招募参与者以及无法将某些结果与纤维肌痛症症状相关联或与用于控制症状的药物治疗的副作用相关联有关。
纤维肌痛症的影响似乎会对女性的双人性欲和单一性欲产生负面影响。此外，年龄或服用抗抑郁药等其他因素可能导致这些患者的性欲降低。López-Rodríguez MM、Pérez Fernández A、Hernández-Padilla JM 等人。纤维肌痛症患者的双人性欲和单一性欲：一项对照研究。性医学杂志 2019；16：1518-1528。
